• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于网络药理学、分子对接及体内实验探讨泄浊化瘀益气通络方治疗尿酸肾病的机制

Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments.

作者信息

Fan Lifei, Guo Yuqin, Wu Qingmei, Hu Tingting, Chen Xiaomei, Guo Jing, Liu Ying, Lu Yuhui, Lin Min

机构信息

College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.

出版信息

Evid Based Complement Alternat Med. 2023 Feb 21;2023:6931644. doi: 10.1155/2023/6931644. eCollection 2023.

DOI:10.1155/2023/6931644
PMID:36865745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9974263/
Abstract

BACKGROUND

Xiezhuo Huayu Yiqi Tongluo Formula (XHYTF) consists of 14 Chinese herbal medicines. In this study, we investigated the potential mechanism of XHYTF in the treatment of uric acid nephropathy (UAN) through network pharmacology, molecular docking, and in vivo methods.

METHODS

Using various pharmacological databases and analysis platforms, information on the active ingredients and targets of Chinese herbal medicine was collected, and UAN disease targets were retrieved using OMIM, Gene Cards, and NCBI. Then common target proteins were integrated. A Drug-Component-Target (D-C-T) map was constructed to screen core compounds and build a protein-protein interaction (PPI) network. Further, Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed for common targets, and a Drug-Component-Target-Pathway (D-C-T-P) network diagram was constructed. The molecular docking simulation was performed to verify the binding affinity between core components and hub targets. Subsequently, the UAN rat model was established, followed by the collection of serum and renal tissues. The expression levels of indicators in the serum were determined using an enzyme-linked immunosorbent assay. The pathological changes of renal tissues were detected using H & E staining and Masson staining. The expression of related proteins in renal tissue was detected by western blot.

RESULTS

In the study, 216 active ingredients and 439 targets in XHYTF were screened, and 868 targets were identified as being related to UAN. Among them, 115 were common targets. Based on the D-C-T network, quercetin, luteolin, -sitosterol, and stigmasterol were observed to be the key active ingredients of XHYTF that were effective against UAN. The analysis of the PPI network revealed TNF, IL6, AKT1, PPARG, and IL1 as the 5 key targets. GO enrichment analysis revealed that the pathways were mainly concentrated in cell killing, regulation of signaling receptor activity, and other activities. Subsequently, KEGG pathway analysis revealed that multiple signaling pathways, including the HIF-1, PI3K-Akt, IL-17, and other signaling pathways, were closely related to the action of XHYTF. All 5 key targets were confirmed to interact with all core active ingredients. In vivo experiments indicated that XHYTF significantly reduced blood uric acid and creatinine levels, alleviated inflammatory cell infiltration in kidney tissues, reduced the levels of serum inflammatory factors such as TNF- and IL1, and ameliorated renal fibrosis in rats with UAN. Finally, western blot revealed decreased levels of PI3K and AKT1 proteins in the kidney, which confirmed the hypothesis.

CONCLUSION

Collectively, our observations demonstrated that XHYTF significantly protects kidney function, including alleviation of inflammation and renal fibrosis via multiple pathways. This study provided novel insights into the treatment of UAN using traditional Chinese medicines.

摘要

背景

泻浊化瘀益气通络方(XHYTF)由14味中药组成。在本研究中,我们通过网络药理学、分子对接和体内实验方法探讨了XHYTF治疗尿酸肾病(UAN)的潜在机制。

方法

利用各种药理学数据库和分析平台,收集中药活性成分和靶点信息,并通过在线人类孟德尔遗传数据库(OMIM)、基因卡片(Gene Cards)和美国国立生物技术信息中心(NCBI)检索UAN疾病靶点。然后整合共同的靶蛋白。构建药物-成分-靶点(D-C-T)图谱以筛选核心化合物并构建蛋白质-蛋白质相互作用(PPI)网络。此外,对共同靶点进行基因本体(GO)富集分析和京都基因与基因组百科全书(KEGG)通路分析,并构建药物-成分-靶点-通路(D-C-T-P)网络图。进行分子对接模拟以验证核心成分与枢纽靶点之间的结合亲和力。随后,建立UAN大鼠模型,接着收集血清和肾组织。使用酶联免疫吸附测定法测定血清中指标的表达水平。使用苏木精-伊红(H&E)染色和Masson染色检测肾组织的病理变化。通过蛋白质免疫印迹法检测肾组织中相关蛋白的表达。

结果

本研究筛选出XHYTF中的216种活性成分和439个靶点,并确定868个靶点与UAN相关。其中,115个为共同靶点。基于D-C-T网络,观察到槲皮素、木犀草素、β-谷甾醇和豆甾醇是XHYTF中对UAN有效的关键活性成分。PPI网络分析显示肿瘤坏死因子(TNF)、白细胞介素6(IL6)、蛋白激酶B1(AKT1)、过氧化物酶体增殖物激活受体γ(PPARG)和白细胞介素1(IL1)为5个关键靶点。GO富集分析显示这些通路主要集中在细胞杀伤、信号受体活性调节等活动中。随后,KEGG通路分析显示包括缺氧诱导因子-1(HIF-1)、磷脂酰肌醇-3激酶-蛋白激酶B(PI3K-Akt)、白细胞介素-17(IL-17)等多个信号通路与XHYTF的作用密切相关。所有5个关键靶点均被证实与所有核心活性成分相互作用。体内实验表明,XHYTF显著降低血尿酸和肌酐水平,减轻肾组织中的炎性细胞浸润,降低血清炎性因子如TNF-α和IL-1的水平,并改善UAN大鼠的肾纤维化。最后,蛋白质免疫印迹法显示肾脏中PI3K和AKT1蛋白水平降低,证实了这一假设。

结论

总体而言,我们的观察结果表明,XHYTF通过多种途径显著保护肾功能,包括减轻炎症和肾纤维化。本研究为使用中药治疗UAN提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/e8604fd051aa/ECAM2023-6931644.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/8c19f2dd9b0c/ECAM2023-6931644.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/ffaa68c1ed31/ECAM2023-6931644.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/44f88845d429/ECAM2023-6931644.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/1a09dc9c54a9/ECAM2023-6931644.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/536da1b2001b/ECAM2023-6931644.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/c2a1ddb2beb6/ECAM2023-6931644.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/71cae43012b1/ECAM2023-6931644.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/e8604fd051aa/ECAM2023-6931644.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/8c19f2dd9b0c/ECAM2023-6931644.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/ffaa68c1ed31/ECAM2023-6931644.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/44f88845d429/ECAM2023-6931644.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/1a09dc9c54a9/ECAM2023-6931644.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/536da1b2001b/ECAM2023-6931644.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/c2a1ddb2beb6/ECAM2023-6931644.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/71cae43012b1/ECAM2023-6931644.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b75/9974263/e8604fd051aa/ECAM2023-6931644.008.jpg

相似文献

1
Mechanism of Xiezhuo Huayu Yiqi Tongluo Formula in the Treatment of Uric Acid Nephropathy Based on Network Pharmacology, Molecular Docking, and In Vivo Experiments.基于网络药理学、分子对接及体内实验探讨泄浊化瘀益气通络方治疗尿酸肾病的机制
Evid Based Complement Alternat Med. 2023 Feb 21;2023:6931644. doi: 10.1155/2023/6931644. eCollection 2023.
2
Gleditsiae Sinensis Fructus ingredients and mechanism in anti-asthmatic bronchitis research.槐角成分及其在抗支气管哮喘中的作用机制研究。
Phytomedicine. 2024 Oct;133:155857. doi: 10.1016/j.phymed.2024.155857. Epub 2024 Jul 11.
3
Potential Molecular Mechanisms of Ephedra Herb in the Treatment of Nephrotic Syndrome Based on Network Pharmacology and Molecular Docking.基于网络药理学和分子对接的麻黄草治疗肾病综合征的潜在分子机制。
Biomed Res Int. 2022 Jul 5;2022:9214589. doi: 10.1155/2022/9214589. eCollection 2022.
4
Integrated plasma pharmacochemistry and network pharmacology to explore the mechanism of Gerberae Piloselloidis Herba in treatment of allergic asthma.整合血浆药物化学与网络药理学以探究鹅不食草治疗过敏性哮喘的机制。
J Ethnopharmacol. 2022 Nov 15;298:115624. doi: 10.1016/j.jep.2022.115624. Epub 2022 Aug 12.
5
Network pharmacology analysis combined with experimental validation to explore the therapeutic mechanism of Schisandra Chinensis Mixture on diabetic nephropathy.网络药理学分析结合实验验证探索五味子合剂治疗糖尿病肾病的作用机制。
J Ethnopharmacol. 2023 Feb 10;302(Pt A):115768. doi: 10.1016/j.jep.2022.115768. Epub 2022 Oct 22.
6
Study on the Potential Mechanism of Tonifying Kidney and Removing Dampness Formula in the Treatment of Postmenopausal Dyslipidemia Based on Network Pharmacology, Molecular Docking and Experimental Evidence.基于网络药理学、分子对接和实验证据的补肾祛湿方治疗绝经后血脂异常的潜在机制研究。
Front Endocrinol (Lausanne). 2022 Jul 7;13:918469. doi: 10.3389/fendo.2022.918469. eCollection 2022.
7
Exploring the pharmacological components and effective mechanism of Mori Folium against periodontitis using network pharmacology and molecular docking.采用网络药理学和分子对接技术探究桑白皮治疗牙周炎的药效物质基础及作用机制。
Arch Oral Biol. 2022 Jul;139:105391. doi: 10.1016/j.archoralbio.2022.105391. Epub 2022 Mar 21.
8
Yiqi Huayu decoction alleviates bleomycin-induced pulmonary fibrosis in rats by inhibiting senescence.益气化瘀汤通过抑制衰老减轻博来霉素诱导的大鼠肺纤维化。
Front Pharmacol. 2022 Oct 28;13:1033919. doi: 10.3389/fphar.2022.1033919. eCollection 2022.
9
The mechanism of Epimedium in the treatment of coronary atherosclerotic heart disease based on network pharmacology, molecular docking, and in vitro studies.基于网络药理学、分子对接和体外研究的淫羊藿治疗冠状动脉粥样硬化性心脏病的机制。
Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2478-2488. doi: 10.26355/eurrev_202204_28482.
10
Exploration of Potential Targets and Molecular Mechanisms of the Yiqi Jianpi Tongqiao Formula in Treating Allergic Rhinitis Mouse Model based on Network Pharmacology and Molecular Docking.基于网络药理学和分子对接技术探讨益气健脾通窍方治疗变应性鼻炎小鼠模型的潜在靶点及分子机制
Curr Comput Aided Drug Des. 2024 May 24. doi: 10.2174/0115734099299714240516160158.

引用本文的文献

1
Qigui-Yishen decoction delays renal fibrosis in mice with chronic kidney disease by regulating TM and PAI-1.芪归益肾汤通过调节TM和PAI-1延缓慢性肾脏病小鼠肾纤维化。
Am J Transl Res. 2024 Jun 15;16(6):2358-2368. doi: 10.62347/GHOV4912. eCollection 2024.
2
PPARG and the PTEN-PI3K/AKT Signaling Axis May Cofunction in Promoting Chemosensitivity in Hypopharyngeal Squamous Cell Carcinoma.PPARG与PTEN-PI3K/AKT信号轴可能共同作用促进下咽鳞状细胞癌的化疗敏感性。
PPAR Res. 2024 Mar 11;2024:2271214. doi: 10.1155/2024/2271214. eCollection 2024.
3
Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma.

本文引用的文献

1
Protective Effects of Quercetin on Oxidative Stress-Induced Tubular Epithelial Damage in the Experimental Rat Hyperoxaluria Model.槲皮素对实验性大鼠高草酸尿症模型中氧化应激诱导的肾小管上皮损伤的保护作用
Medicina (Kaunas). 2021 Jun 3;57(6):566. doi: 10.3390/medicina57060566.
2
Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency.高尿酸血症通过促进尿酸氧化酶缺乏大鼠的自噬和 NLRP3 介导的炎症导致肾脏损伤。
Dis Model Mech. 2021 Mar 24;14(3):dmm048041. doi: 10.1242/dmm.048041.
3
Lipophilic Extract and Tanshinone IIA Derived from Attenuate Uric Acid Nephropathy through Suppressing Oxidative Stress-Activated MAPK Pathways.
基于网络药理学的方法研究α-茄碱抗神经胶质瘤的作用及机制。
BMC Complement Med Ther. 2023 Oct 21;23(1):371. doi: 10.1186/s12906-023-04215-1.
脂溶性提取物和丹参酮 IIA 通过抑制氧化应激激活的 MAPK 通路来减轻尿酸肾病。
Am J Chin Med. 2020;48(6):1455-1473. doi: 10.1142/S0192415X20500718. Epub 2020 Sep 15.
4
Editorial: Network Pharmacology and Traditional Medicine.社论:网络药理学与传统医学
Front Pharmacol. 2020 Aug 4;11:1194. doi: 10.3389/fphar.2020.01194. eCollection 2020.
5
Rhein attenuates renal inflammatory injury of uric acid nephropathy via lincRNA-Cox2/miR-150-5p/STAT1 axis.瑞因通过 lincRNA-Cox2/miR-150-5p/STAT1 轴减轻尿酸肾病的肾炎症损伤。
Int Immunopharmacol. 2020 Aug;85:106620. doi: 10.1016/j.intimp.2020.106620. Epub 2020 Jun 5.
6
Uric acid and inflammation in kidney disease.尿酸与肾脏病中的炎症反应。
Am J Physiol Renal Physiol. 2020 Jun 1;318(6):F1327-F1340. doi: 10.1152/ajprenal.00272.2019. Epub 2020 Mar 30.
7
Uric acid in CKD: has the jury come to the verdict?慢性肾脏病中的尿酸:陪审团是否已做出裁决?
J Nephrol. 2020 Aug;33(4):715-724. doi: 10.1007/s40620-020-00702-7. Epub 2020 Jan 13.
8
Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.与非布司他和别嘌醇相关的急性肾损伤:一项上市后研究。
Arthritis Res Ther. 2019 Nov 8;21(1):229. doi: 10.1186/s13075-019-2011-y.
9
The role of oxidative stress-mediated apoptosis in the pathogenesis of uric acid nephropathy.氧化应激介导的细胞凋亡在尿酸肾病发病机制中的作用。
Ren Fail. 2019 Nov;41(1):616-622. doi: 10.1080/0886022X.2019.1633350.
10
Galangin Suppresses Renal Inflammation via the Inhibition of NF-B, PI3K/AKT and NLRP3 in Uric Acid Treated NRK-52E Tubular Epithelial Cells.姜黄素通过抑制 NF-B、PI3K/AKT 和尿酸处理的 NRK-52E 肾小管上皮细胞中的 NLRP3 抑制肾脏炎症。
Biomed Res Int. 2019 May 26;2019:3018357. doi: 10.1155/2019/3018357. eCollection 2019.